THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

International Flavors & Fragrances Inc. (IFF)

3/23/2006 Proxy Information

Dr. Blobel is a cofounder of Chromocell Corporation (‘‘Chromocell’’). Chromocell pays Dr. Blobel a nominal advisory fee of $2,000 per year for scientific advice to Chromocell with respect to its research efforts and programs. Dr. Blobel does not receive any other compensation from Chromocell (other than reimbursement of certain expenses) and is not an officer, director or employee of Chromocell. In addition, Dr. Blobel has received equity as a founder of Chromocell and has a 3.9% equity interest in Chromocell.

The Company and Chromocell have entered into research agreements under which Chromocell is conducting a program to develop for the Company three distinct cell lines with related high throughput assays to assist the Company in creating new flavor ingredients. Through early 2006, Chromocell supplied two of the cell lines and assays to the Company and was paid $2 million therefor. The efficacy of the third and final cell line and assay is being considered by the parties. If deemed acceptable, it will result in an additional $1 million payment and bring to a close the current research agreements between the Company and Chromocell.

The Company and Chromocell have entered into a supply agreement under which the Company will have an exclusive right to use the cell lines and assays for the development of new flavor materials. The supply agreement is anticipated to have the Company pay Chromocell milestone payments and a running royalty on new products discovered using Chromocell technology.

In a separate agreement dated June 15, 2004, the Company and Chromocell entered into a Convertible Promissory Note. The Company loaned Chromocell $2 million at an annual interest rate of 6%, with principal and interest payable on December 31, 2007. The Company has the right, but not the obligation, to convert the debt into equity upon the occurrence of certain specified events.

3/24/2005 Proxy Information

Dr. Blobel is a cofounder of Chromocell Corporation ("Chromocell"). Chromocell pays Dr. Blobel a nominal advisory fee of $2,000 per year for scientific advice to Chromocell with respect to its research efforts and programs. Dr. Blobel does not receive any other compensation from Chromocell (other than reimbursement of certain expenses) and is not an officer, director or employee of Chromocell. In addition, Dr. Blobel has received equity as a founder of Chromocell and has a 3.9% equity interest in Chromocell.

The Company and Chromocell have entered into research agreements under which Chromocell is conducting a program to develop for the Company cell lines to assist the Company in creating new flavor ingredients. In 2004, the Company paid Chromocell $1,684,000 to develop cell lines and assays. The Company also spent $820,000 to purchase equipment used to support this program. The equipment is currently located in Chromocell's facility, and will be relocated to Company research facilities upon delivery of the final cell lines and assays by Chromocell.

The Company and Chromocell have entered into a supply agreement under which the Company will have an exclusive right to use the cell lines and assays for the development of new flavor materials. The supply agreement is anticipated to have the Company pay Chromocell milestone payments and a running royalty on new products discovered using Chromocell technology. In a separate agreement dated June 15, 2004, the Company and Chromocell entered into a Convertible Promissory Note. The Company loaned Chromocell 2 million dollars at an annual interest rate of 6%, with principal and interest payable on December 31, 2007. The Company has the right, but not the obligation, to convert the debt into equity upon the occurrence of certain specified events.

3/26/2004 Proxy Information

The members of the Compensation Committee during 2003 were Messrs. Georgescu, Martinez, Van Dyke, and Mr. Henry P. van Ameringen. Mr. van Ameringen served on the committee until his retirement from the Board on May 14, 2003. Mr. Van Dyke served on the committee until January 2004. Mr. Van Dyke is Senior Vice President of Salomon Smith Barney Inc., which has received commissions for brokerage services performed in connection with securities transactions on behalf of the Company and its retirement plans which amounted to $388,073 in 2003. Mr. van Ameringen was a former officer (until 1979) of the Company.

Dr. Blobel is a cofounder of Chromocell Corporation ("Chromocell"). Chromocell pays Dr. Blobel a nominal advisory fee of $2,000 per year for scientific advice to Chromocell with respect to its research efforts and programs. Dr. Blobel does not receive any other compensation from Chromocell (other than reimbursement of expenses). In addition, Dr. Blobel has received equity as a founder of Chromocell and has a 3.9% equity interest in Chromocell.

The Company and Chromocell have entered into a Research Agreement under which Chromocell has engaged in a program to develop for the Company cell lines to assist the Company in creating new flavor and fragrance ingredients. In 2003 the Company paid Chromocell $590,000 to fund the research program and acquire certain rights to the cell lines. In addition, the Company has also retained the right to provide equity capital or debt financing to Chromocell at such times as Chromocell may determine to increase its equity or debt. The terms of any such equity investment or debt financing will be negotiated in good faith at arms-length between the Company and Chromocell. The Company is currently finalizing an additional research agreement pursuant to which the Company will pay Chromocell $1,119,000 to continue the initial research program and $565,000 to fund a new research program to develop additional cell lines. The Company is also considering an equity capital and/or debt financing arrangement with Chromocell.

3/25/2003 Proxy Information

Alexandra A. Herzan is the niece of Mr. van Ameringen, who will retire as a director as of the 2003 Annual Meeting.

Dr. Blobel is a co-founder of Chromocell Corporation ("Chromocell"). Chromocell and Dr. Blobel are contemplating an Advisory Agreement under which Dr. Blobel will provide scientific advice to Chromocell with respect to its research efforts and programs. Dr. Blobel receives no cash compensation from Chromocell, but it is contemplated that he will receive equity and certain options to purchase additional equity in Chromocell in connection with his advisory activities.

The Company and Chromocell are negotiating agreements under which it is anticipated that Chromocell will engage in a research program to develop for the Company a new product that will assist the Company in creating new flavor and fragrance ingredients. The Company will pay Chromocell $590,000 to fund the research program, a portion of which may be in the form of an equity contribution to Chromocell. It is also anticipated that the Company will have the right to provide additional equity capital or debt financing to Chromocell at such times as Chromocell may determine to increase its equity or debt. The terms of any such equity investment or debt financing will be negotiated in good faith at arms-length between the Company and Chromocell.